Phaseline

Targets › GDF15

GDF15 (Growth/differentiation factor 15): drug programs, companies and trials

4 programs from 4 companies in 9 trials: 5 Phase 2, 4 Phase 1; Oncology, Other; next expected readout Dec 2026.

Hormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite. The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future. (UniProt, Q99988)

Open in Phaseline: the race on GDF15, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pfizerponsegromab
GDF15 neutralizing monoclonal antibody
GDF15Phase 2CachexiaJan 2028
CatalYmVisugromab (CTL-002)
GDF-15 neutralizing antibody
GDF15Phase 2Metastatic Non-Squamous Non-Small Cell Lung Cancer; Unresectable or Metastatic Hepatocellular Carcinoma; Cancer-associated Cachexia; Solid Tumor, AdultApr 2028
AVEO PharmaceuticalsAV-380
anti-GDF-15 monoclonal antibody
GDF15Phase 1CachexiaDec 2026
Kexing BiopharmGB18
GDF15 monoclonal antibody antagonist
GDF15Phase 1Cachexia; Cancer; Cancer Cachexia (CC)Sep 2027

Conditions

Metastatic Non-Squamous Non-Small Cell Lung Cancer (2) Cachexia (2) Unresectable or Metastatic Hepatocellular Carcinoma (1) Cancer-associated Cachexia (1) Solid Tumor, Adult (1) Cachexia; Cancer (1) Cancer Cachexia (CC) (1)

Modalities

antibody (2), small molecule (1), protein or peptide (1)

Companies

CatalYm (1) Kexing Biopharm (1) AVEO Pharmaceuticals (1) Pfizer (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.